Abstract
Mokashi and associates1 have recently shared the Cleveland Clinic's intermediate-term experience with reimplantation of tricuspid aortic valves (TAV) and bicuspid aortic valves (BAV). In a propensity score–matched analysis, the authors demonstrated excellent 5-year outcomes with 100% survival in the BAV and 98% survival in the TAV group. Freedom from reoperation in the BAV and TAV cohort was 94% and 98%, respectively. Although both procedures were done with equal safety and short-term outcomes, the authors were concerned due to greater transvalvular gradients and less ventricular reverse remodeling in the BAV cohort, as well as less freedom from reoperations in the BAV cohort at 8 years (77%).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
